A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
SN BioScience
IMGT Co., Ltd.
Taiho Oncology, Inc.
Revolution Medicines, Inc.
Bristol-Myers Squibb
CARsgen Therapeutics Co., Ltd.
Ono Pharmaceutical Co. Ltd
Akeso
Ono Pharmaceutical Co. Ltd
Actuate Therapeutics Inc.
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Gilead Sciences
Lumos Pharma
Lumos Pharma
Leaf Vertical Inc.